611 W. Union Street
Benson, AZ 85602
(520) 586-0800

member support line
M-F 5pm-8pm
24/7 weekends/holidays

AzCH Nurse Assist Line


611 W. Union Street
Benson, AZ 85602
(520) 586-0800

AzCH Nurse Assist Line


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...

Medical Disorders
Basic InformationLookupsLatest News
AHA News: Health Emergency? Don't Hesitate to Get HelpToo Many Patients, Too Few Ventilators: How U.S. Hospitals Cope With COVID-19AI Might Spot Which COVID-19 Patients Are at Risk of Severe DiseaseWhat Dental Offices Are Doing to Prevent Coronavirus Infection?A Parent's Guide to Fighting Coronavirus StressTrump Extends Social Distancing to April 30 as COVID-19 Cases SurgeRecovery From Mild Brain Trauma Takes Longer Than Expected: StudyStaying at Home During the Pandemic? Use Technology to Stay ConnectedAHA News: Understanding the Basics of 'Herd Immunity'Multiple Measures of Social Distancing Required to Slow Coronavirus: StudyCough, Fever, Fatigue? Head to CDC's Online Coronavirus Symptom CheckerThree Countries Have Kept Coronavirus in Check; Here's How They Did ItTrial Finds Acupuncture May Help Prevent MigrainesSevere COVID-19 Might Injure the HeartWhy Are Teens, Millennials Ignoring Coronavirus Warnings?An Expert's Guide to Fact-Checking Coronavirus Info OnlineLivestock, Poultry Safe From Coronavirus: ExpertWuhan Study Shows How Social Distancing Is Saving LivesU.S. Hospital Beds Were Already Maxed Out Before Coronavirus PandemicFDA Warns of Defective EpiPen DangersPoll Finds High Anxiety in the Time of CoronavirusCould Robots Be Deployed to Front Line in Fighting COVID-19?COVID-19 May Force Some Cancer Patients to Delay TreatmentWhat People With Parkinson's Need to Know About COVID-19How to Weather Social Isolation During Coronavirus PandemicCOVID-19 Infection Likely Worse for Vapers, SmokersWhen Arteries Narrow, Chest Pain Can Come Earlier for Women Than MenLoss of Sense of Smell Could Be Early Sign of Coronavirus InfectionMany Drugs Already Approved by FDA May Have Promise Against COVID-19The Other Side of COVID-19: Milder Cases, Healthy RecoveryAs Coronavirus Myths Multiply, Experts Sort Fact From FictionA Third of Americans Ordered to Stay at Home; Summer Olympics Postponed for One YearWeight-Loss Surgery May Cut Risk of Heart Attack, StrokeFDA Warns Americans to Beware of Fake COVID-19 Test KitsTaking Steroids for Rheumatoid Arthritis, IBD? Your Odds for Hypertension May RiseWhat Does a Self-Quarantine Look Like?National Guard Activated in 3 States as U.S. Coronavirus Cases Top 34,000U.S. Coronavirus Cases Pass 26,000, With 1 in 4 Americans Under 'Shelter-in-Place' OrdersRaking Your Leaves to the Edge of Your Yard an Invitation to TicksNew Drug Helps Shrink Inoperable Tumors in KidsCoronavirus Crisis Should Put Elective Surgeries on Hold, Doctors' Group SaysAlmost Half of Coronavirus Patients Have Digestive SymptomsNearly 40% of Hospitalizations in U.S. COVID-19 Cases Involve Adults Under 55Healthy Living at Home to Ward Off CoronavirusWhat You Need to Know About Coronavirus If You Have AsthmaStudy Suggests COVID-19 Might Follow Seasonal PatternTrump Signs Massive Relief Package Into Law as U.S. Coronavirus Cases Reach 10,000AHA News: A Look at Allergies and Heart Health, With Tips to Endure Pollen Season Amid Coronavirus FearsNew Coronavirus Wasn't Made in a Lab, Genomic Study ShowsWho's Most at Risk From Coronavirus?
Questions and AnswersLinksBook Reviews
Related Topics

Men's Health
Women's Health

Drug Offers Hope Against Tough-to-Treat Chronic Cough

HealthDay News
by -- Robert Preidt
Updated: Feb 26th 2020

new article illustration

WEDNESDAY, Feb. 26, 2020 (HealthDay News) -- Anywhere from 4% to 10% of adults have troublesome chronic cough, defined as an unexplained cough lasting more than eight weeks. But a new drug may offer some long-sought relief.

Reporting Feb. 25 in The Lancet Respiratory Medicine, British researchers said the experimental drug, called gefapixant, blocks a cellular receptor that's key to the cough reflex.

"Many patients with a chronic cough are driven to seek treatment because of the significant negative impact it can have on their quality of life, but at the moment physicians are unable to help," noted study leader Jacky Smith, a professor at the University of Manchester, in England.

This "is the first study to report a treatment that is safe and effective over the longer term," Smith said in a journal news release. She added that "phase 3 trials are already underway with an even larger group of people and over a longer time frame."

The trial was funded by the drug's maker, Merck, and involved 253 American and British participants. All had suffered from an unexplained or untreatable cough that had lasted for an average of almost 15 years. Three-quarters were women, most (70%) had never smoked, and patients averaged 60 years of age.

The patients received either a "dummy" placebo or gefapixant twice a day for three months. Those who received the drug were given one of three doses: 7.5 milligrams (mg), 20 mg, or 50 mg.

Everyone was asked to keep a "cough diary," and they also wore a device that recorded their coughing over a 24-hour period.

Before the study began, patients coughed about 24 to 29 times an hour. But after the trial period, the placebo group coughed 18 times an hour, compared with 11 coughs an hour among patients in the 50 mg gefapixant group -- a 37% difference.

The patients in the 7.5 mg and 20 mg gefapixant groups had slightly lower rates of coughing than those in the placebo group, but the differences were not statistically significant, the study authors noted.

The most common side effect among patients in the study was a change in their sense of taste.

Two experts unconnected to the study said any drug that helps ease chronic cough is long overdue.

"Whoever creates the treatment to control chronic cough will help millions of patients lead a more comfortable life," said Dr. Theodore Maniatis, medical director at Staten Island University Hospital in New York City. He said that once the usual suspects for cough -- asthma, acid reflux and others -- are ruled out, "patients remaining are assumed to have a hypersensitive cough reflex mechanism."

Gefapixant "acts by antagonizing the activity of one of the receptors (a group of chemicals at nerve endings) and thereby decreasing the transmission of nerve impulses to the cough centers," Maniatis explained.

He hopes the new drug proves successful because, "in the past, the only treatment that was minimally successful was narcotic cough suppressants."

Dr. Margarita Oks is a pulmonologist at Lenox Hill Hospital in New York City. She noted that there was a strong placebo effect in the study, but "the authors adjusted their results for the placebo effect," strengthening the validity of the results.

"The drug under investigation is too new to be sure of its effectiveness and its side effects," Oks said, "but there are some promising results so far."

More information

Harvard Medical School has more on chronic cough.